1. Home
  2. DAC vs VRDN Comparison

DAC vs VRDN Comparison

Compare DAC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Danaos Corporation

DAC

Danaos Corporation

HOLD

Current Price

$161.74

Market Cap

2.6B

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$21.89

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAC
VRDN
Founded
1972
2006
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.1B
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
DAC
VRDN
Price
$161.74
$21.89
Analyst Decision
Buy
Strong Buy
Analyst Count
2
14
Target Price
$112.50
$35.46
AVG Volume (30 Days)
101.2K
1.1M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
3.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,706,000.00
Revenue This Year
N/A
$13.73
Revenue Next Year
N/A
$279.00
P/E Ratio
$4.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$83.56
$13.18
52 Week High
$163.64
$34.29

Technical Indicators

Market Signals
Indicator
DAC
VRDN
Relative Strength Index (RSI) 71.30 46.44
Support Level $121.29 $21.40
Resistance Level N/A $23.84
Average True Range (ATR) 2.89 0.88
MACD 0.27 -0.24
Stochastic Oscillator 87.94 28.87

Price Performance

Historical Comparison
DAC
VRDN

About DAC Danaos Corporation

Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: